Figure S1, schematic concept of the three-dimensional dark-field microscopy imaging setup; Figure S2, dynamic light scattering measurement of anti-CA125 and anti-Biotin antibody-conjugated 80 nm spherical gold plasmonic nanoparticles (PNPs); Figure S3, dynamic light scattering measurement and UV-visible absorption spectra of anti-CA125 and anti-Biotin antibody-conjugated PNPs treated with various concentrations of CA125 antigen; Figure S4, color quantization for monomer, dimer, and trimer based on the red/ green intensity ratios (R/G ratios); Figure S5, mathematical model for evaluating the systemic error of the color quantization method for bound PNPs in MUC16 binding on the surface of the cell; Figure S6, PNP-based digital cytometric assay on ovarian cancer cells (OVCAR3) with and without centrifugation; Figure S7, optimization of incubation conditions for the ratio of treated PNPs to cells in the PNP-based digital cytometric assay on ovarian cancer cells (OVCAR3); Figure S8, cell membrane mask generated by a deep convolutional neural network (U-Net) to exclude unbound PNPs nearby the cells in the enumeration of bound PNPs on the surface of cells; Figure S9, longitudinal study of bound MUC16/CA125 on the surface of EOC patient's PBMCs over a 17 month period at 1 month intervals; Figure S10, evaluation of the specific binding ability of anti-CA125 PNPs toward its targets on the patient's and healthy subject's PBMCs with various PBMC to PNP ratios; Figure S11, dark-field microscopy image montages of anti-CA125 PNPs bound to individual PBMCs in samples from five healthy donors and five serous invasive EOC patients; Figure S12, flow cytometric analysis for the evaluation of bound MUC16 on the surface of PBMCs from five healthy donors and five serous invasive ovarian cancer patients; Figure S13, scanning electron microscopy images of OVCAR3 clone treated with antibody-conjugated PNPs; and Table S1, ages and the CA125 levels in the serum of healthy donors and ovarian cancer patients (PDF)